Global Microbiome Therapeutics Market

2.1    Scope of Work
2.2    Key Questions Answered in the Report

3.1    Global Microbiome Therapeutics Market: Research Methodology
3.2    Data Sources
3.3    Secondary Data Sources
3.4    Market Estimation Model
3.5    Criteria for Company Profiling

4.1    Market Size and Future Growth Potential
4.2    Historical Trends

5.1    Regulatory Landscape
         5.1.1    Regulatory Requirements for Live Biotherapeutic Products (LBPs)
5.2    Patent Landscape
         5.2.1    Patent Filing Analysis
         5.2.2    Key Players Patent Portfolio
         5.2.3    Key Players Patent Expiration Analysis
5.3    Financing Landscape
         5.3.1    Financing Stratification (as Per Raised Financing Value)
         5.3.2    Year on Year Financing Analysis (FY2017-3Q2020)
         5.3.3    Investment Heat Map
5.4    Pipeline Landscape
         5.4.1    Competitive Landscaping
         5.4.2    Pipeline Analysis
                     5.4.2.1    By Developmental Phase
                     5.4.2.2    By Route of Administration
                     5.4.2.3    By Type of Microbiome Strategy
                     5.4.2.4    By Target Therapy Area
5.5    Partnership Landscape
5.6    Government Initiatives

6.1    Market Drivers
         6.1.1    Significant External Funding for Executing Research and Therapeutic Innovation
         6.1.2    Increasing Adoption of Inorganic Growth Strategies in the Market
6.2    Market Restraints
         6.2.1    Payer Uncertainty and Outcome-Based Pricing
         6.2.2    Insufficient Application-Based Research Hindering Market Pull
         6.2.3    FMT Manufacturing Issues
6.3    Market Opportunities
         6.3.1    Entry of Major Players for the Development of Microbiome Therapeutics
         6.3.2    Growing Eminence of Microbiome Therapeutics in Cancer Treatment

7.1    Key Strategies and Developments
7.2    Synergistic Activities
7.3    Regulatory Accreditations
7.4    Mergers and Acquisitions
7.5    Market Share Analysis
7.6    Growth Share Analysis (Opportunity Mapping)
         7.6.1    By Geography
         7.6.2    By Company

8.1    Overview
8.2    Gastrointestinal and Infectious Diseases
8.3    Other Diseases

9.1    Overview
9.2    North America
         9.2.1    Overview
         9.2.2    U.S.
         9.2.3    Canada
9.3    Europe
         9.3.1    Overview
         9.3.2    France
         9.3.3    Sweden
         9.3.4    Germany
         9.3.5    U.K.
         9.3.6    Rest-of-Europe
9.4    Asia-Pacific (APAC)
         9.4.1    Overview
         9.4.2    Japan
         9.4.3    Australia
         9.4.4    China
         9.4.5    India
         9.4.6    Rest-of-Asia-Pacific
9.5    Rest-of-the-World
         9.5.1    Overview

10.1.1    Overview
10.2    4D Pharma plc
           10.2.1    Company Overview
           10.2.2    Role of 4D Pharma plc in Global Microbiome Therapeutics Market
           10.2.3    Financials
           10.2.4    SWOT Analysis
10.3    AOBiome
           10.3.1    Company Overview
           10.3.2    Role of AOBiome in the Global Microbiome Therapeutics Market
           10.3.3    SWOT Analysis
10.4    Finch Therapeutics
           10.4.1    Company Overview
           10.4.2    Role of Finch Therapeutics in Global Microbiome Therapeutics Market
           10.4.3    SWOT Analysis
10.5    Ferring Pharmaceuticals
           10.5.1    Company Overview
           10.5.2    Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
           10.5.3    Company Overview
           10.5.4    Role of Rebiotix Inc. in Global Microbiome Therapeutics Market
           10.5.5    SWOT Analysis
10.6    Immuron Limited
           10.6.1    Company Overview
           10.6.2    Role of Immuron in Global Microbiome Therapeutics Market
           10.6.3    Financials
           10.6.4    SWOT Analysis
10.7    MaaT Pharma
           10.7.1    Company Overview
           10.7.2    Role of MaaT Pharma in Global Microbiome Therapeutics Market
           10.7.3    SWOT Analysis
10.8    Naked Biome
           10.8.1    Company Overview
           10.8.2    Role of Naked Biome in Global Microbiome Therapeutics Market
           10.8.3    SWOT Analysis
10.9    OxThera AB
           10.9.1    Company Overview
           10.9.2    Role of OxThera AB in Global Microbiome Therapeutics Market
           10.9.3    SWOT Analysis
10.10    Quorum Innovations
             10.10.1    Company Overview
             10.10.2    Role of Quorum Innovations, LLC in Global Microbiome Therapeutics Market
             10.10.3    SWOT Analysis
10.11    Sanofi S.A.
             10.11.1    Company Overview
             10.11.2    Role of Sanofi S.A. in Global Microbiome Therapeutics Market
             10.11.3    Financials
             10.11.4    Key Insights About the Financial Health of the Company
             10.11.5    SWOT Analysis
10.12    Seres Therapeutics, Inc.
             10.12.1    Company Overview
             10.12.2    Role of Seres Therapeutics, Inc. in Global Microbiome Therapeutics Market
             10.12.3    Financials
             10.12.4    Key Insights About Financial Health of the Company
             10.12.5    SWOT Analysis
10.13    Synthetic Biologics
             10.13.1    Company Overview
             10.13.2    Role of Synthetic Biologics, Inc. in Global Microbiome Therapeutics Market
             10.13.3    Financials
             10.13.4    SWOT Analysis
10.14    Taisho Pharmaceutical
             10.14.1    Company Overview
             10.14.2    Biofermin Pharmaceutical Co. Ltd. (A Subsidiary of Taisho Pharmaceutical)
             10.14.3    Company Overview
             10.14.4    Role of Taisho Pharmaceutical in Global Microbiome Therapeutics Market
             10.14.5    Financial
             10.14.6    Key Insights about the Financial Health of the Company
             10.14.7    SWOT Analysis
10.15    Vedanta Biosciences, Inc.
             10.15.1    Company Overview
             10.15.2    Role of Vedanta Biosciences, Inc. in Global Microbiome Therapeutics Market
             10.15.3    SWOT Analysis
10.16    Pendulum Therapeutics
             10.16.1    Company Overview
             10.16.2    Role of Pendulum Therapeutics in Global Microbiome Therapeutics Market
             10.16.3    SWOT Analysis

Table 5.1:    Global Microbiome Therapeutics Market (Key Players Patent Portfolio)
Table 5.2:    Patent Expiration Analysis
Table 5.3:    Key Players Investors Portfolio
Table 5.4:    Key Players Investors Portfolio
Table 5.5:    Partnership Landscaping
Table 5.6:    Government Initiatives in Microbiome Therapeutics
Table 6.1:    Microbiome Collaborations
Table 9.1:    EU Funding of Microbiome Research Under FP7 and H2020

Figure 1:    Impact Analysis of Market Drivers and Market Challenges on Global Microbiome Therapeutics Market
Figure 2:    Global Microbiome Therapeutics Market (by Target Therapy Area), $Million, 2020 and 2030
Figure 3:    Global Microbiome Therapeutics Market (by Region), $Million, 2019-2030
Figure 2.1:    Global Microbiome Therapeutics Market Segmentation
Figure 3.1:    Global Microbiome Therapeutics Market Research Methodology
Figure 3.2:    Primary Research Methodology
Figure 3.3:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4:    Top-Down Approach (Segment-Wise Analysis)
Figure 4.1:    Global Microbiome Therapeutics Market, $Million, 2019-2030
Figure 4.2:    Historical Evolution of Microbiome
Figure 5.1:    Chemistry, Manufacturing, and Control (CMC) Information of LBPs by FDA
Figure 5.2:    Patent Landscape of Microbiome Therapeutics Market  (by Company and Region)
Figure 5.3:    Key Players Financing Stratification
Figure 5.4:    Financing Analysis, $Million, FY2017-3Q2020
Figure 5.5:    Number of Pipeline Candidates (by Developmental Phase)
Figure 5.6:    Number of Pipeline Candidates (by Route of Administration)
Figure 5.7:    Number of Pipeline Candidates (by Type of Product)
Figure 5.8:    Number of Pipeline Candidates (by Target Therapy Area)
Figure 6.1:    Market Dynamics of Global Microbiome Therapeutics Market
Figure 6.2:    Financing Activities Breakout, 2017-2019
Figure 6.3:    Overall Financing Raised by Microbiome Companies, $Million,  January 2017 – 3Q 2020
Figure 6.4:    Synergistic Activities, 2017-2019
Figure 7.2:    Synergistic Activities Share (by Company), January 2017-October 2020
Figure 7.3:    Accreditations Share (by Company), January 2017- October 2020
Figure 7.4:    Mergers and Acquisitions (by Company), January 2017- October 2020
Figure 7.5:    Market Share Analysis for the Global Microbiome Therapeutics Market, 2018 and 2019
Figure 7.6:    Growth Share Analysis (by Geography)
Figure 7.7:    Growth Share Analysis (by Company)
Figure 8.1:    Global Microbiome Therapeutics Market (by Target Therapy Area), 2020 and 2030
Figure 8.2:    Number of Pipeline Candidates for Gastrointestinal and Infectious Diseases Indications
Figure 8.3:    Global microbiome therapeutics market (Gastrointestinal and Infectious Diseases), 2019-2030
Figure 8.4:    Global Microbiome Therapeutics Market (Other Diseases), 2023-2030
Figure 9.1:    Global Microbiome Therapeutics Market (by Region), 2020 and 2030
Figure 9.2:    North America Microbiome Therapeutics Market, 2019-2030
Figure 9.3:    North America: Market Dynamics
Figure 9.4:    North America Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.5:    U.S. Microbiome Therapeutics Market, 2019-2030
Figure 9.6:    Canada Microbiome Therapeutics Market, 2019-2030
Figure 9.7:    Europe Microbiome Therapeutics Market, 2019-2030
Figure 9.8:    Europe: Market Dynamics
Figure 9.9:    Europe Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.10:    France Microbiome Therapeutics Market, 2019-2030
Figure 9.11:    Sweden Microbiome Therapeutics Market, 2019-2030
Figure 9.12:    Germany Microbiome Therapeutics Market, 2019-2030
Figure 9.13:    U.K. Microbiome Therapeutics Market, 2019-2030
Figure 9.14:    Rest-of-Europe Microbiome Therapeutics Market, 2019-2030
Figure 9.15:    Asia-Pacific Microbiome Therapeutics Market, 2019-2030
Figure 9.16:    Asia-Pacific: Market Dynamics
Figure 9.17:    Asia-Pacific Microbiome Therapeutics Market (by Country), 2020 and 2030
Figure 9.18:    Japan Microbiome Therapeutics Market, 2019-2030
Figure 9.19:    Australia Microbiome Therapeutics Market, 2019-2030
Figure 9.20:    China Microbiome Therapeutics Market, 2019-2030
Figure 9.21:    India Microbiome Therapeutics Market, 2019-2030
Figure 9.22:    Rest-of-Asia-Pacific Microbiome Therapeutics Market, 2019-2030
Figure 9.23:    Rest-of-the-World Microbiome Therapeutics Market, 2019-2030
Figure 10.1:    Total Number of Companies Profiled
Figure 10.2:    4D Pharma plc: Overall Product Portfolio
Figure 10.3:    4D Pharma plc.: Overall Financials, 2018-2019
Figure 10.4:    4D Pharma plc: SWOT Analysis
Figure 10.5:    AOBiome.: Overall Product Portfolio
Figure 10.6:    AOBiome: SWOT Analysis
Figure 10.7:    Finch Therapeutics: Overall Product Portfolio
Figure 10.8:    Finch Therapeutics: SWOT Analysis
Figure 10.9:    Rebiotix Inc.: Overall Product Portfolio
Figure 10.10:    Rebiotix Inc.: SWOT Analysis
Figure 10.11:    Immuron: Overall Product Portfolio
Figure 10.12:    Immuron: Overall Financials, 2018-2020
Figure 10.13:    Immuron: Research and Development Expenditure, 2018-2020
Figure 10.14:    Immuron: SWOT Analysis
Figure 10.15:    MaaT Pharma.: Overall Product Portfolio
Figure 10.16:    MaaT Pharma: SWOT Analysis
Figure 10.17:    Naked Biome: Overall Product Portfolio
Figure 10.18:    Naked Biome: SWOT Analysis
Figure 10.19:    OxThera AB: Overall Product Portfolio
Figure 10.20:    OxThera AB: SWOT Analysis
Figure 10.21:    Quorum Innovations, LLC: Overall Product Portfolio
Figure 10.22:    Quorum Innovations, LLC: SWOT Analysis
Figure 10.23:    Sanofi S.A.: Overall Product Portfolio
Figure 10.24:    Sanofi S.A.: Overall Financials, 2017-2019
Figure 10.25:    Sanofi S.A.: Revenue (by Segment), 2017-2019
Figure 10.26:    Sanofi S.A.: Region Revenue, 2017-2019
Figure 10.27:    Sanofi S.A.: Research and Development Expenditure, 2017-2019
Figure 10.28:    Sanofi S.A.: SWOT Analysis
Figure 10.29:    Seres Therapeutics, Inc.: Overall Product Portfolio
Figure 10.30:    Seres Therapeutics, Inc.: Overall Financials, 2017-2019
Figure 10.31:    Seres Therapeutics Inc.: R&D Expenditure, 2017-2019
Figure 10.32:    Seres Therapeutics Inc.: SWOT Analysis
Figure 10.33:    Synthetic Biologics, Inc.: Overall Product Portfolio
Figure 10.34:    Synthetic Biologics, Inc.: Overall Financials, 2017-2019
Figure 10.35:    Synthetic Biologics, Inc.: SWOT Analysis
Figure 10.36:    Taisho Pharmaceutical Co., Ltd.: Overall Product Portfolio
Figure 10.37:    Taisho Pharmaceutical Co., Ltd.: Overall Financials, 2017-2019
Figure 10.38:    Taisho Pharmaceutical Co., Ltd. (by Segment), 2017-2019
Figure 10.39:    Taisho Pharmaceutical Co., Ltd. (by Region), 2019
Figure 10.40:    Taisho Pharmaceutical Co., Ltd.: R&D Expenditure, 2018-2019
Figure 10.41:    Taisho Pharmaceutical Co., Ltd.: SWOT Analysis
Figure 10.42:    Vedanta Biosciences, Inc.: Overall Product Portfolio
Figure 10.43:    Vedanta Biosciences, Inc.: SWOT Analysis
Figure 10.44:    Whole Genome Inc.: Overall Product Portfolio
Figure 10.45:    Whole Biome Inc.: SWOT Analysis